GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.
From the first evidence that the immune system could recognize tumors, different types of tumor antigens have been identified and deeply characterized. Several different approaches aimed at targeting these antigens have already been the subject of clinical studies. In this field, the GSK Biologicals' approach relying on recombinant proteins combined with an immunological Adjuvant System in a specific clinical setting, has entertained hopes of developing a new class of well tolerated anti-cancer therapy. This methodology led to promising advances with MAGE-A3 immunotherapy in NSCLC and has the potential to be applied to all tumor types.
Brichard
Vincent G
VG
Cancer Immunotherapeutics R&D, GlaxoSmithKline Biologicals, Rue de l'Institut, Rixensart, Belgium. vincent.brichard@gskbio.com
Lejeune
Diane
D
D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D009363:Neoplasm Proteins / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy*; D009842:Oligopeptides / Q000276:immunology / Q000627:therapeutic use*
D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; D009363:Neoplasm Proteins; D009842:Oligopeptides; C056289:GSK peptide